Eveline E. Vietsch

1.1k total citations
25 papers, 802 citations indexed

About

Eveline E. Vietsch is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Eveline E. Vietsch has authored 25 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Eveline E. Vietsch's work include Pancreatic and Hepatic Oncology Research (16 papers), Cancer Genomics and Diagnostics (9 papers) and MicroRNA in disease regulation (5 papers). Eveline E. Vietsch is often cited by papers focused on Pancreatic and Hepatic Oncology Research (16 papers), Cancer Genomics and Diagnostics (9 papers) and MicroRNA in disease regulation (5 papers). Eveline E. Vietsch collaborates with scholars based in United States, Netherlands and Spain. Eveline E. Vietsch's co-authors include Anton Wellstein, Suthee Rapisuwon, Garrett T. Graham, Bhaskar Kallakury, Fen Wang, Yuhao Shi, Mahandranauth A. Chetram, Weiying Zhang, Swati Gupta and Chunling Yi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Cancer Research.

In The Last Decade

Eveline E. Vietsch

24 papers receiving 796 citations

Peers

Countries citing papers authored by Eveline E. Vietsch

Since Specialization

Citations

This map shows the geographic impact of Eveline E. Vietsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eveline E. Vietsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eveline E. Vietsch more than expected).

Fields of papers citing papers by Eveline E. Vietsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eveline E. Vietsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eveline E. Vietsch. The network helps show where Eveline E. Vietsch may publish in the future.

Co-authorship network of co-authors of Eveline E. Vietsch

This figure shows the co-authorship network connecting the top 25 collaborators of Eveline E. Vietsch. A scholar is included among the top collaborators of Eveline E. Vietsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eveline E. Vietsch. Eveline E. Vietsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival 2024 ·Pancreatology ·(unknown), (unknown), (unknown), (unknown), (unknown), Yunlei Li, Andrew Stubbs, Michael Doukas, (unknown), Lara R. Heij, Georg Wiltberger, Lola Alonso, Núria Malats, Bas Groot Koerkamp, Eveline E. Vietsch, (unknown), Casper H.J. van Eijck	0
2	FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction 2023 ·European Journal of Cancer ·(unknown), (unknown), (unknown), Eveline E. Vietsch, (unknown), (unknown), Dana A. M. Mustafa, (unknown), Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen	5
3	B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients 2023 ·Frontiers in Immunology ·Eveline E. Vietsch, (unknown), (unknown), (unknown), Roeland F. de Wilde, (unknown), Anne Loes van den Boom, Bas Groot Koerkamp, Pascal G. Doornebosch, (unknown), Ariadne H.A.G. Ooms, (unknown), Marcella Willemsen, Joachim G.J.V. Aerts, (unknown), Noel F.C.C. de Miranda, Thierry van den Bosch, Yvonne M. Mueller, Peter D. Katsikis, Casper H.J. van Eijck	5
4	Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients 2022 ·Frontiers in Immunology ·(unknown), Willem A. Dik, Dana A. M. Mustafa, Eveline E. Vietsch, Marc G. Besselink, Reno Debets, Bas Groot Koerkamp, Brigitte C.M. Haberkorn, Marjolein Y.V. Homs, Quisette P. Janssen, Saskia Luelmo, Leonie J. Mekenkamp, (unknown), (unknown), Johanna W. Wilmink, Casper H.J. van Eijck, (unknown)	15
5	Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors 2022 ·Cancers ·Ivana Peran, Eveline E. Vietsch, Gai Yan, Anna T. Riegel, Anton Wellstein	1
6	Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma 2021 ·Clinical Cancer Research ·(unknown), Jiang Chang, (unknown), Michail Doukas, (unknown), (unknown), Eveline E. Vietsch, Joris Pothof, Bas Groot Koerkamp, Casper H.J. van Eijck	41
7	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study 2021 ·International Journal of Molecular Sciences ·(unknown), Marjolein Y.V. Homs, (unknown), Thierry van den Bosch, Koop Bosscha, Marc G. Besselink, Bert A. Bonsing, Jan Willem B. de Groot, Thomas M. Karsten, Bas Groot Koerkamp, Brigitte C.M. Haberkorn, Saskia Luelmo, Leonie J. Mekenkamp, Dana A. M. Mustafa, Johanna W. Wilmink, Casper H.J. van Eijck, Eveline E. Vietsch, (unknown)	15
8	Circulating cytokine levels as biomarkers for response to FOLFIRINOX chemotherapy in pancreatic cancer patients 2021 ·HPB ·(unknown), (unknown), Dana A. M. Mustafa, Eveline E. Vietsch, Casper H.J. van Eijck	1
9	Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation 2021 ·SHILAP Revista de lepidopterología ·Sarah Martinez, Eveline E. Vietsch, (unknown), Marcel O. Schmidt, Matthew D. Park, Archana Ramesh, Michael Lindberg, Giuseppe Giaccone, Anna T. Riegel, Ana Barac, Keith Unger, Anton Wellstein	2
10	Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer 2020 ·Clinica Chimica Acta ·(unknown), Eveline E. Vietsch, Dana A. M. Mustafa, Yunlei Li, Casper H.J. van Eijck	12
11	Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice 2020 ·Gastroenterology ·Ivana Peran, Sivanesan Dakshanamurthy, Matthew McCoy, Anastasia Mavropoulos, Bedilu Allo, Aimy Sebastian, Nicholas R. Hum, (unknown), Kelly A. Martin, Michael J. Pishvaian, Eveline E. Vietsch, Anton Wellstein, Michael B. Atkins, Louis M. Weiner, Andrew A. Quong, Gabriela G. Loots, Stephen Yoo, Shahin Assefnia, Stephen W. Byers	67
12	Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection 2019 ·Applied Sciences ·Eveline E. Vietsch, Ivana Peran, Mustafa Suker, Thierry P. P. van den Bosch, (unknown), Johan M. Kros, Casper H.J. van Eijck, Anton Wellstein	8
13	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients 2019 ·Cancers ·(unknown), Eveline E. Vietsch, Dana A. M. Mustafa, Marc G. Besselink, Bas Groot Koerkamp, Casper H.J. van Eijck	21
14	Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis 2019 ·Pancreas ·Sandeep Nadella, Julian Burks, (unknown), Juan Wang, Hong Cao, Bhaskar Kallakury, (unknown), Simina M. Boca, (unknown), Irene Collins, Eveline E. Vietsch, Mariaelena Pierobon, (unknown), (unknown), Laufey T. Ámundadóttir, (unknown), Narayan Shivapurkar, Jill P. Smith	8
15	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer 2018 ·Cancer Genetics ·Eveline E. Vietsch, Garrett T. Graham, Justine N. McCutcheon, Aamir Javaid, Giuseppe Giaccone, John L. Marshall, Anton Wellstein	4
16	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer 2017 ·Cancer Genetics ·Eveline E. Vietsch, Garrett T. Graham, Justine N. McCutcheon, Aamir Javaid, Giuseppe Giaccone, John L. Marshall, Anton Wellstein	45
17	Circulating biomarkers to monitor cancer progression and treatment 2016 ·Computational and Structural Biotechnology Journal ·Suthee Rapisuwon, Eveline E. Vietsch, Anton Wellstein	104
18	Abstract A73: De-convoluting therapeutic resistance in a pancreatic cancer model: Pharmacogenomic evaluation of intratumoral clonal heterogeneity 2015 ·Cancer Research ·Eveline E. Vietsch, John K. Simmons, Ivana Peran, (unknown), Beverly A. Mock, Anton Wellstein	2
19	Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma 2014 ·Science Signaling ·Weiying Zhang, (unknown), Yuhao Shi, Mark Manzano, Alias Smith, Garrett T. Graham, Swati Gupta, Eveline E. Vietsch, (unknown), (unknown), Mahandranauth A. Chetram, (unknown), Fen Wang, Bhaskar Kallakury, Jeffrey A. Toretsky, Anton Wellstein, Chunling Yi	293
20	Dietary downregulation of mutant p53 levels via glucose restriction 2012 ·Cell Cycle ·Olga Rodriguez, (unknown), Vamsi Krishna Kolukula, Eveline E. Vietsch, Jason Catania, Anju Preet, (unknown), Jill Bargonetti, Anton Wellstein, Chris Albanese, Maria Laura Avantaggiati	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact